TREATMENT WITH LINAGLIPTIN AND STUDY IN VARIATIONS OF SERUM URIC ACID LEVELS IN PATIENTS OF TYPE 2 DIABETES MELLITUS

Shubham Agarwal*,
Arvind Mishra**,
KKGupta***,
Ravi Misra****,
Shilpa*****

*Senior Resident, Department of Medicine
**Professor, Department of Medicine
***Associate Professor, Department of Medicine
****Professor, Department of Medicine
*****Senior Resident, Department of Medicine King George’s Medical University, Lucknow, UP

ABSTRACT

Coexistent hyperuricemia with type 2 diabetes mellitus is routinely and increasingly reported and is emerging as a matter of growing concern globally. Apart from the risk of related complications, it also asks for additional strategy of management. Linagliptin, a DPP-4 inhibitor is recently reported to cause decrease in serum uric acid levels via its action on xanthine oxidase enzyme which it inhibits. Present work comprised of 172 subjects which included 90 cases and 82 controls. Case subjects were kept on Linagliptin while controls were kept on hypoglycemic agents other than DPP-4 inhibitors. Serial serum uric acid levels were observed in both groups at 3, 6 and 9 monthly intervals. In case subjects, regular decline in serum uric acid levels (mean) at 3,6 and 9 months were 6.45+/-0.28, 5.35+/-0.78 and 4.56+/- 0.47 mg/dl as accordingly. All these observations were statistically significant (p<000.1). No significant reduction in serum uric acid levels was observed in control subjects. Study advocates efficacy of Linagliptin in reducing serum uric acid levels in patients of Type 2 Diabetes Mellitus

Keywords: Hyperuricemia, Xanthine oxidase,Uric acid